Uploaded March 2021 | Updated November 2026, 3 hours ago
Richard and I recently spent an hour together discussing today's startup landscape in science and medicine, and he compared Genentech's culture to what he sees as a concerning drop in scientific rigor inside some new companies. He attributes this to the intense pressure to publish, coupled with the increase in venture activity in life sciences.
Read more: gv.com/news/richard-scheller-genetics-drug-development
Richard and I recently spent an hour together discussing today's startup landscape in science and medicine, and he compared Genentech's culture to what he sees as a concerning drop in scientific rigor inside some new companies. He attributes this to the intense pressure to publish, coupled with the increase in venture activity in life sciences.
Read more: gv.com/news/richard-scheller-genetics-drug-development










